Compare FNWB & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | MXCT |
|---|---|---|
| Founded | 1923 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 86.5M |
| IPO Year | 2012 | 2021 |
| Metric | FNWB | MXCT |
|---|---|---|
| Price | $9.13 | $0.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $13.50 | $7.50 |
| AVG Volume (30 Days) | 27.4K | ★ 1.3M |
| Earning Date | 04-29-2026 | 04-06-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $176,000.00 | ★ $38,627,000.00 |
| Revenue This Year | $19.24 | N/A |
| Revenue Next Year | $8.90 | $9.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.05 | $0.64 |
| 52 Week High | $10.98 | $3.49 |
| Indicator | FNWB | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 29.81 | 39.34 |
| Support Level | $7.56 | $0.75 |
| Resistance Level | $9.50 | $1.79 |
| Average True Range (ATR) | 0.31 | 0.06 |
| MACD | -0.09 | 0.03 |
| Stochastic Oscillator | 5.86 | 57.77 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.